Prime medicine reports first quarter 2025 financial results and provides business updates

-- initial data from phase 1/2 trial of pm359 for p47 phox cgd expected in 2025 -- -- ind and/or cta for pm577 for wilson's disease on-track for 1h 2026 -- -- unveiled potentially best-in-class program for aatd; ind and/or cta filing targeted for mid-2026 -- cambridge, mass., may 08, 2025 (globe newswire) --  prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended march 31, 2025 and provided a business update.
PRME Ratings Summary
PRME Quant Ranking